A revolution in the treatment of osteoarthritis
Scarcell Therapeutics has developed a unique allogeneic cell therapy that regenerates damaged cartilage.
Our straightforward bioproduction has been validated and our cost of goods is extremely low.
Scarcell’s Gingival Fibroblasts cell therapy presents two breakthrough advances compared to competition:
1. Exceptional healing properties compared to conventional cell therapy products:
• Ability to regenerate cartilage
• Long-lasting therapeutic effect due to cell preservation compared to the other current cell therapies
• Powerful and long-lasting anti-inflammatory activity
• Allogeneic: accessible for the entire population without the need for immunosuppressive drugs
2. Highly efficient and scalable GMP bioproduction process resulting in significantly lower manufacturing costs compared to existing cell therapies (MSCs, iPS/ES, and CAR-T cells).
Company Details
- Employees
- 6
- Address
- 17, Rue De L'amiral Hamelin, Paris,île-De-France 75116,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- scarcellvet.com
- HQ
- Paris, Île-de-France
Scarcell Therapeutics Questions
Scarcell Therapeutics's website is scarcellvet.com
Scarcell Therapeutics's LinkedIn profile is https://fr.linkedin.com/company/scarcelltherapeutics
Scarcell Therapeutics has
6 employees.
View email and phone details for 6
employees at Scarcell Therapeutics.
Scarcell Therapeutics's industry is
Biotechnology Research
Scarcell Therapeutics's top competitors are
Polygon Therapeutics,
Theravectys,
Oncovita,
Altevax Biotech,
Evexta Bio,
Ipsirius,
Inotrem,
Ptc Therapeutics, Inc.,
Scarcell Therapeutics,
Ennodc.
Scarcell Therapeutics's categories are Biotechnology Research
